Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of nasopharyngeal carcinoma WHO type II or III~  * Stage I-IV disease~ * Newly diagnosed disease~* Performance status~  * Patients ≤ 16 years of age: Lansky 60-100%~ * Patients \> 16 years of age: Karnofsky 60-100%~* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min~* Creatinine based on age/gender as follows:~  * No greater than 0.4 mg/dL (for patients 1 month to \< 6 months of age)~ * No greater than 0.5 mg/dL (for patients 6 months to \< 1 year of age)~ * No greater than 0.6 mg/dL (for patients 1-2 years of age)~ * No greater than 0.8 mg/dL (for patients \< 6 years of age)~ * No greater than 1.0mg/dL (for patients 6 to \< 10 years of age)~ * No greater than 1.2 mg/dL (for patients 10 to \< 13 years of age)~ * No greater than 1.4 mg/dL (for female patients 13 to ≥ 16 years of age)~ * No greater than 1.5 mg/dL (for male patients 13 to \< 16 years of age)~ * No greater than 1.7 mg/dL (for male patients ≥ 16 years of age)~* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age~* AST or ALT \< 2.5 times ULN for age~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Stratum I (radiotherapy, chemoprotective agent) (Type: EXPERIMENTAL): Patients undergo radiotherapy 5 days a week for 8 weeks. Patients also receive amifostine subcutaneously on the same days they undergo radiotherapy.
- Stratum II (chemotherapy, chemoprotective agent, radiotherapy) (Type: EXPERIMENTAL): Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiotherapy and receive amifostine as in stratum I. Patients also receive 3 courses of cisplatin as before.

Based on this trial design, predict the completion outcome and termination type (if applicable).